{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:04:18Z","timestamp":1789380258876,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,22]],"date-time":"2012-10-22T00:00:00Z","timestamp":1350864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1756-8722-5-67","type":"journal-article","created":{"date-parts":[[2012,10,22]],"date-time":"2012-10-22T14:14:05Z","timestamp":1350915245000},"source":"Crossref","is-referenced-by-count":20,"title":["Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-na\u00efve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial"],"prefix":"10.1186","volume":"5","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriet K","family":"Khuageva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Garicochea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achiel","family":"Van Hoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Soubeyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Buckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixie-Lee","family":"Esseltine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panteli","family":"Theocharous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Enny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusri A","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,22]]},"reference":[{"key":"260_CR1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.07.003","volume":"45","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW: Treatment of follicular non-Hodgkin's lymphoma: the old and the new. Semin Hematol. 2008, 45: S2-S6.","journal-title":"Semin Hematol"},{"key":"260_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1586\/ehm.10.45","volume":"3","author":"VP Kenkre","year":"2010","unstructured":"Kenkre VP, Kahl BS: Follicular lymphoma: emerging therapeutic strategies. Expert Rev Hematol. 2010, 3: 485-495. 10.1586\/ehm.10.45.","journal-title":"Expert Rev Hematol"},{"key":"260_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011, 377: 42-51. 10.1016\/S0140-6736(10)62175-7.","journal-title":"Lancet"},{"key":"260_CR4","doi-asserted-by":"publisher","first-page":"vii151","DOI":"10.1093\/annonc\/mdq287","volume":"21","author":"M Ghielmini","year":"2010","unstructured":"Ghielmini M: Follicular lymphoma. Ann Oncol. 2010, 21: vii151-vii153. 10.1093\/annonc\/mdq287.","journal-title":"Ann Oncol"},{"key":"260_CR5","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","volume":"24","author":"Q Liu","year":"2006","unstructured":"Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006, 24: 1582-1589. 10.1200\/JCO.2005.03.3696.","journal-title":"J Clin Oncol"},{"key":"260_CR6","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P: Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009, 27: 4555-4562. 10.1200\/JCO.2008.21.3991.","journal-title":"J Clin Oncol"},{"key":"260_CR7","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Rranz-Saez R, Au WY, Bellei M, Brice P, Caballero D: Follicular lymphoma international prognostic index. Blood. 2004, 104: 1258-1265. 10.1182\/blood-2003-12-4434.","journal-title":"Blood"},{"key":"260_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1586\/ehm.09.34","volume":"2","author":"S Luminari","year":"2009","unstructured":"Luminari S, Cox MC, Montanini A, Federico M: Prognostic tools in follicular lymphomas. Expert Rev Hematol. 2009, 2: 549-562. 10.1586\/ehm.09.34.","journal-title":"Expert Rev Hematol"},{"key":"260_CR9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s12185-010-0674-x","volume":"92","author":"P Solal-Celigny","year":"2010","unstructured":"Solal-Celigny P, Cahu X, Cartron G: Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?. Int J Hematol. 2010, 92: 246-254. 10.1007\/s12185-010-0674-x.","journal-title":"Int J Hematol"},{"key":"260_CR10","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","volume":"15","author":"S Montoto","year":"2004","unstructured":"Montoto S, Lopez-Guillermo A, Altes A, Perea G, Ferrer A, Camos M, Villela L, Bosch F, Esteve J, Cervantes F: Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol. 2004, 15: 1484-1489. 10.1093\/annonc\/mdh406.","journal-title":"Ann Oncol"},{"key":"260_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000253026","volume":"122","author":"V Formica","year":"2009","unstructured":"Formica V, Norman AR, Cunningham D, Wotherspoon A, Oates J, Chong G: Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. Acta Haematol. 2009, 122: 193-199. 10.1159\/000253026.","journal-title":"Acta Haematol"},{"key":"260_CR12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Celigny P: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires, Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997, 15: 1110-1117.","journal-title":"J Clin Oncol"},{"key":"260_CR13","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1002\/cncr.25280","volume":"116","author":"F Morschhauser","year":"2010","unstructured":"Morschhauser F, Mounier N, Sebban C, Brice P, Solal-Celigny P, Tilly H, Feugier P, Ferme C, Copin MC, Lamy T: Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent\/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucemies et Autres Maladies du Sang (GOELAMS). Cancer. 2010, 116: 4299-4308. 10.1002\/cncr.25280.","journal-title":"Cancer"},{"key":"260_CR14","first-page":"783","volume":"95","author":"M Federico","year":"2000","unstructured":"Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P: Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases Intergruppo Italiano Linfomi. Blood. 2000, 95: 783-789.","journal-title":"Blood"},{"key":"260_CR15","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","volume":"28","author":"T Relander","year":"2010","unstructured":"Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD: Prognostic factors in follicular lymphoma. J Clin Oncol. 2010, 28: 2902-2913. 10.1200\/JCO.2009.26.1693.","journal-title":"J Clin Oncol"},{"key":"260_CR16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2010.0129","volume":"8","author":"M Rummel","year":"2010","unstructured":"Rummel M: Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice. J Natl Compr Canc Netw. 2010, 8: S1-S14.","journal-title":"J Natl Compr Canc Netw"},{"key":"260_CR17","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008, 26: 4579-4586. 10.1200\/JCO.2007.13.5376.","journal-title":"J Clin Oncol"},{"key":"260_CR18","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004, 104: 3064-3071. 10.1182\/blood-2004-04-1323.","journal-title":"Blood"},{"key":"260_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/annonc\/mdm511","volume":"19","author":"MJ Overman","year":"2008","unstructured":"Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L: The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol. 2008, 19: 553-559.","journal-title":"Ann Oncol"},{"key":"260_CR20","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH van Oers","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, Veer M, Vranovsky A, Holte H: Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010, 28: 2853-2858. 10.1200\/JCO.2009.26.5827.","journal-title":"J Clin Oncol"},{"key":"260_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","volume":"115","author":"N Di Bella","year":"2010","unstructured":"Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, Cochran EW, Dien PY, Lyons R, Schlegel PJ: Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010, 115: 475-480. 10.1182\/blood-2009-08-233155.","journal-title":"Blood"},{"key":"260_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1158\/1078-0432.CCR-08-2647","volume":"16","author":"OA O'Connor","year":"2010","unstructured":"O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, Gonen M, Dumitrescu O, Sarasohn D, Butos J: Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res. 2010, 16: 719-726. 10.1158\/1078-0432.CCR-08-2647.","journal-title":"Clin Cancer Res"},{"key":"260_CR23","doi-asserted-by":"crossref","first-page":"338a","DOI":"10.1182\/blood.V116.21.338.338","volume":"116","author":"V Ribrag","year":"2010","unstructured":"Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdullah R, Delarue R, Boue F, Bron D, Feugier P, Haioun C: Final results of a randomized phase 2 multicenter study of two bortezomib schedules in patients with recurrent or refractory follicular lymphoma. Groupe d'Etude Des Lymphomes De l'Adulte (GELA) study FL-05 [abstract]. Blood. 2010, 116: 338a-","journal-title":"Blood"},{"key":"260_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2141.2010.08340.x","volume":"151","author":"A Agathocleous","year":"2010","unstructured":"Agathocleous A, Rohatiner A, Rule S, Hunter H, Kerr JP, Neeson SM, Matthews J, Strauss S, Montoto S, Johnson P: Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol. 2010, 151: 346-353. 10.1111\/j.1365-2141.2010.08340.x.","journal-title":"Br J Haematol"},{"key":"260_CR25","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","volume":"27","author":"S de Vos","year":"2009","unstructured":"de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D: Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009, 27: 5023-5030. 10.1200\/JCO.2008.17.7980.","journal-title":"J Clin Oncol"},{"key":"260_CR26","doi-asserted-by":"crossref","first-page":"1617a","DOI":"10.1182\/blood.V116.21.1617.1617","volume":"116","author":"A Chiappella","year":"2010","unstructured":"Chiappella A, Pregno P, Zinzani PL, Evangelista A, Fabbri A, Facchetti F, Ferreri AJM, Franceschetti S, Freilone R, Gargantini L: Weekly infusion of bortezomib in combination with rituximab in relapsed\/refractory indolent non-follicular and mantle cell lymphoma is safe and effective: two-years analysis of phase II trial BRIL06 of Intergruppo Italiano Linfomi (IIL) [abstract]. Blood. 2010, 116: 1617a-","journal-title":"Blood"},{"key":"260_CR27","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1002\/cncr.25792","volume":"117","author":"RA Baiocchi","year":"2011","unstructured":"Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA: Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011, 117: 2442-2451. 10.1002\/cncr.25792.","journal-title":"Cancer"},{"key":"260_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","volume":"12","author":"B Coiffier","year":"2011","unstructured":"Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, De VS: Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011, 12: 773-784. 10.1016\/S1470-2045(11)70150-4.","journal-title":"Lancet Oncol"},{"key":"260_CR29","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","volume":"28","author":"E Bachy","year":"2010","unstructured":"Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le GS, Delmer A, Bordessoule D, Tilly H, Corront B: Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival\u2013a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2010, 28: 822-829. 10.1200\/JCO.2009.22.7819.","journal-title":"J Clin Oncol"},{"key":"260_CR30","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/annonc\/mdp053","volume":"20","author":"SA van de Schans","year":"2009","unstructured":"van de Schans SA, Steyerberg EW, Nijziel MR, Creemers GJ, Janssen-Heijnen ML, van Spronsen DJ: Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol. 2009, 20: 1697-1702. 10.1093\/annonc\/mdp053.","journal-title":"Ann Oncol"},{"key":"260_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","volume":"14","author":"JM Vose","year":"2008","unstructured":"Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD, Armitage JO: Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant. 2008, 14: 36-42.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 6","key":"260_CR32","doi-asserted-by":"crossref","first-page":"vi59","DOI":"10.1093\/annonc\/mdr388","volume":"22","author":"M Dreyling","year":"2011","unstructured":"Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011, 22 (Suppl 6): vi59-vi63.","journal-title":"Ann Oncol"},{"key":"260_CR33","doi-asserted-by":"crossref","first-page":"484","DOI":"10.6004\/jnccn.2011.0046","volume":"9","author":"AD Zelenetz","year":"2011","unstructured":"Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ: Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2011, 9: 484-560.","journal-title":"J Natl Compr Canc Netw"},{"key":"260_CR34","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","volume":"14","author":"MS Czuczman","year":"2008","unstructured":"Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ: Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008, 14: 1561-1570. 10.1158\/1078-0432.CCR-07-1254.","journal-title":"Clin Cancer Res"},{"key":"260_CR35","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","volume":"67","author":"AR Jazirehi","year":"2007","unstructured":"Jazirehi AR, Vega MI, Bonavida B: Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 2007, 67: 1270-1281. 10.1158\/0008-5472.CAN-06-2184.","journal-title":"Cancer Res"},{"key":"260_CR36","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1080\/10428190802357071","volume":"49","author":"MI Vega","year":"2008","unstructured":"Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O, Bonavida B: The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma. 2008, 49: 1982-1994. 10.1080\/10428190802357071.","journal-title":"Leuk Lymphoma"},{"key":"260_CR37","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999, 17: 3835-3849.","journal-title":"J Clin Oncol"},{"key":"260_CR38","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas NCI Sponsored International Working Group. J Clin Oncol. 1999, 17: 1244-","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-5-67.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-8722-5-67\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-5-67.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:54:40Z","timestamp":1594774480000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-5-67"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,22]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["260"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-5-67","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,22]]},"article-number":"67"}}